KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma.

Teele Kuusk, Axel Bex

Hematol Oncol Clin North Am 37(5) 907-920

PMID37369611
PMCID-
DOI10.1016/j.hoc.2023.05.020
发表日期2023-06-27
摘要

摘要

In locally advanced RCC, 6 phase 3 randomized controlled trials (RCTs) were designed in the perioperative setting with immune checkpoint inhibitor (ICI) monotherapy or combinations. Adjuvant trials with atezolizumab, pembrolizumab, and nivolumab with ipilimumab reported results, as did the only perioperative trial with nivolumab. Of these, only 1 year of adjuvant pembrolizumab improved disease-free survival (DFS) versus placebo, with the other trials showing no improvement in DFS. In the purely neoadjuvant setting, phase 1 b/2 ICI trials have demonstrated safety, efficacy, and dynamic changes of immune infiltrates, and provide a rationale for randomized trial concepts.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。